Global Hydraulic Press Machine Market to Witness 4.8% CAGR during 2017 - 2023     |   Global Auto-Injectors Market to Witness 18.6% CAGR during 2017 – 2023     |    Global Ammonium Phosphate Market to Witness 3.6% CAGR During 2016 – 2022

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

P&S Market Research - A market research firm

Mammalian Target of Rapamycin Inhibitors Market

P&S Market Research-mTOR Inhibitors Market report

Global Mammalian Target of Rapamycin (mTOR) Inhibitors Market - Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2022

Upcoming Report
Report Code: LS10751
Available Format: pdf

The global mammalian target of rapamycin (mTOR) inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.

The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.

Several ongoing research and development activities for mTOR inhibitors strengthen the pipeline of key vendors. Pharmaceutical companies are investing huge capital for the development of mTOR inhibitors. The pipeline of mTOR inhibitors is crowded with more than 30 drugs. mTOR is a protein of a 289-kDa long chain of serine and threonine kinase. It helps in the synthesis of important cellular proteins, which has a major impact in various aspects of cell growth and differentiation, progression of cell cycle, protein degradation, angiogenesis and apoptosis. mTOR inhibitors bind to a cytoplasmic protein and form a complex, which interacts with mTOR kinase.

Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.

Europe is the second largest market for mTOR inhibitors. During the forecast period, the mTOR inhibitors market would witness highest growth in Asia-Pacific, attributed to increasing number of new entrants, improving healthcare infrastructure, increasing prevalence of chroic diseases and increasing healthcare expenditure.

The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

To request table of contents of the report, please complete the form below :

  

Please fill the form to get the sample pages.

  

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

$6500
Group License

Group License authorizes access of the publication upto 5 users.

$7500
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

$8500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

$10500
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment